Sign up for our monthly newsletter!

Get the latest information and inspirational stories for caregivers, delivered directly to your inbox.

go back

FDA Approves Breakthrough Alzheimer’s Drug Lecanemab

The Guardian


The US Food and Drug Administration (FDA) has approved Lecanemab, a breakthrough drug to treat Alzheimer’s, that is manufactured by biotechnology companies Biogen and Eisai. The drug is an intravenously administered humanized monoclonal antibody that targets amyloid, the toxic protein in the brain linked to the cognitive disease. Lecanemab, marketed as Leqembi, works with the body’s immune system to clear amyloid protein buildup from the brain. Findings from the clinical trial of the drug found that “Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events”.

See full story at The Guardian

More Stories From


brain scan

Alzheimer’s Drugs Are a Ray of Hope

The Guardian

brain with eraser

New Treatment Could Stop Dementia's Damage to the Brain

The Jerusalem Post


Rare Alzheimer’s Mutation Delayed the Onset of Disease

Scientific American

MCI and Beyond

© 2022 MCI and Beyond. All rights reserved.